SinoReg

AbbVie Deutschland GmbH & Co. KG — China drug registrations and re-registration deadlines

9 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2027-02-04.

Approval numberProductCertificate expiresRe-registration deadline (Art. 82)
国药准字HJ20170377OZURDEX
地塞米松玻璃体内植入剂
2027-08-042027-02-04
国药准字HJ20181115Aluvia
洛匹那韦利托那韦片
2027-11-152027-05-15
国药准字HJ20233125RINVOQ
乌帕替尼缓释片
2028-02-132027-08-13
国药准字SJ20191006HUMIRA
阿达木单抗注射液
2029-09-012029-03-01
国药准字SJ20215002HUMIRA
阿达木单抗注射液
2029-09-012029-03-01
国药准字SJ20200007HUMIRA
阿达木单抗注射液
2030-01-062029-07-06
国药准字HJ20150484Lumigan
贝美前列素滴眼液
2030-02-162029-08-16
国药准字SJ20260031EPKINLY
艾可瑞妥单抗注射液
2031-05-112030-11-11
国药准字SJ20260032EPKINLY
艾可瑞妥单抗注射液
2031-05-112030-11-11

Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.

All holders  ·  China re-registration deadline index